BCTX on Nasdaq
BriaCell Therapeutics Corp.
Price unavailable
Last updated Oct 16, 2026.
Overview
-$26.3MNet income, fiscal 20252
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-151.8%Return on equity2
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-07-31 | 2024-07-31 |
|---|---|---|
| Research and development expenses | $21.3M | $27.2M |
| General and administrative expenses | $5.9M | $6.2M |
| Total operating expenses | $27.2M | $33.3M |
| Operating loss | -$27.2M | -$33.3M |
| Financial income (expenses), net | $114.5K | $262.6K |
| Change in fair value of the warrant liability | $758.4K | $28.2M |
| Share of loss on equity investment | -$224.2K | -$106.5K |
| Net loss for the year | -$26.6M | -$4.9M |
| Net loss attributable to non-controlling interest | -$244.3K | -$140.1K |
| Net loss for the year attributable to BriaCell | -$26.3M | -$4.8M |
| Net loss per share attributable to BriaCell - basic | -$62.19 | -$43.68 |
| Net loss per share attributable to BriaCell - diluted | -$62.19 | -$43.68 |
| Weighted average number of shares (*) used in computing net loss per share attributable to ordinary shareholders, basic | 423.1K shares | 109.7K shares |
| Weighted average number of shares (*) used in computing net loss per share attributable to ordinary shareholders, diluted | 423.1K shares | 109.7K shares |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-07-31 | 2025-01-31 | 2024-07-31 |
|---|---|---|---|
| Cash and cash equivalents | $10.5M | $862.1K | |
| Short-term investments | $7.4M | ||
| Amounts receivable and prepaid expenses | $2.1M | $2.8M | |
| Total current assets | $19.9M | $3.7M | |
| Equity investment in BC Therapeutics | $524.3K | $418.5K | |
| Intangible assets, net | $184.5K | $199.8K | |
| Property and equipment, net | $296.8K | $388.2K | |
| Long term prepaid expenses | $717.5K | $1.2M | |
| Total non-current assets | $1.7M | $2.2M | |
| Total assets | $21.6M | $5.9M | |
| Trade payables | $3.3M | $7.2M | |
| Accrued expenses and other payables | $694.3K | $290.4K | |
| Total current liabilities | $4.0M | $7.5M | |
| Warrant liability | $337.7K | $1.1M | |
| Total non-current liabilities | $337.7K | $1.1M | |
| Share Capital of no par value Authorized: unlimited at July 31, 2025 and 2024; Issued and outstanding: 1,883,906 and 121,907 shares at July 31, 2025 and 2024, respectively | $101.7M | $72.2M | |
| Share-based payment reserved | $10.3M | $9.2M | |
| Warrant reserve | $17.7M | $1.8M | |
| Accumulated other comprehensive loss | -$138.7K | -$138.7K | |
| Non-controlling interest | -$546.8K | -$302.5K | |
| Accumulated deficit | -$111.8M | -$85.4M | |
| Total shareholders equity (deficit) | $17.3M | -$2.7M | |
| Total liabilities and shareholders equity (deficit) | $21.6M | $5.9M | |
| Common stock, no par value | $0 | $0 | |
| Common stock, shares issued | 1.9M shares | 121.9K shares | |
| Common stock, shares outstanding | 1.9M shares | 294.7K shares | 121.9K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-07-31 | 2024-07-31 |
|---|---|---|
| Net loss for the year | -$26.6M | -$4.9M |
| Amortization | $15.3K | $15.3K |
| Financial income (expenses), net | -$56.5K | |
| Depreciation | $91.4K | $68.6K |
| Share-based compensation | $776.9K | $1.8M |
| Share of loss on equity investment | $224.2K | $106.5K |
| Change in fair value of warrants | -$758.4K | -$28.2M |
| Decrease (increase) in amounts receivable | $733.6K | -$732.6K |
| Decrease in prepaid expenses | $492.3K | $2.1M |
| (Decrease) increase in accounts payable | -$3.9M | $6.0M |
| Increase (decrease) in accrued expenses and other payables | $753.9K | -$387.3K |
| Net cash used in operating activities | -$28.2M | -$24.1M |
| Purchase of property and equipment | -$456.8K | |
| Purchase of short-term investments, net | -$7.3M | |
| Equity investment in BC Therapeutics | -$330.0K | -$225.0K |
| Net cash used in investing activities | -$7.6M | -$681.8K |
| Proceeds from exercise of warrants | $821.0K | |
| Proceeds from issuance of shares, net of issuance costs | $44.6M | $4.4M |
| Net cash provided by financing activities | $45.4M | $4.4M |
| Increase in cash and cash equivalents | $9.6M | -$20.4M |
Former names
- Ansell Capital Corp.Jun 20, 2014 to Jun 20, 20143
Recent filings
- Jun 26, 20268-K
- Jun 9, 202610-Q
- Jun 3, 20268-K
- Jun 2, 2026424B5
- Mar 31, 20268-K
- Mar 10, 202610-Q
- Mar 9, 20268-K
- Feb 26, 202625-NSE
- Feb 20, 20268-K
- Feb 12, 2026DEF 14A
- Jan 23, 2026SCHEDULE 13G
- Jan 15, 20268-K
- Jan 14, 2026424B4
- Jan 13, 20268-A12B
- Jan 13, 2026CERT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10